A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas

[1]  J. Wargo,et al.  Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab , 2020, Clinical Cancer Research.

[2]  Jeffrey E. Lee,et al.  B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.

[3]  J. Wargo,et al.  B cells are associated with survival and immunotherapy response in sarcoma , 2020, Nature.

[4]  J. Roliński,et al.  Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors , 2019, International journal of molecular sciences.

[5]  J. Castle,et al.  Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution , 2019, Journal of Immunotherapy for Cancer.

[6]  Lanlan Wang,et al.  Increased circulating Tfh to Tfr ratio in chronic renal allograft dysfunction: a pilot study , 2019, BMC Immunology.

[7]  David M. Thomas,et al.  Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas , 2019, Modern Pathology.

[8]  Z. Zeng,et al.  Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape , 2019, Molecular Cancer.

[9]  Xiaosheng Wang,et al.  Correlate tumor mutation burden with immune signatures in human cancers , 2019, BMC Immunology.

[10]  Yoon-La Choi,et al.  Status of programmed death-ligand 1 expression in sarcomas , 2018, Journal of Translational Medicine.

[11]  J. Gu,et al.  Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis. , 2018, Immunotherapy.

[12]  E. Seront,et al.  Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma , 2018, Future science OA.

[13]  M. Fernö,et al.  Stability of oestrogen and progesterone receptor antigenicity in formalin‐fixed paraffin‐embedded breast cancer tissue over time , 2018, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[14]  Kongming Wu,et al.  Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors , 2018, Molecular cancer.

[15]  P. Reichardt.  The Story of Imatinib in GIST - a Journey through the Development of a Targeted Therapy , 2018, Oncology Research and Treatment.

[16]  C. Klein,et al.  A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade , 2018, Nature Network Boston.

[17]  D. Katz,et al.  More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven Treatments. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[18]  E. Baldini,et al.  Neoadjuvant Chemotherapy, Concurrent Chemoradiation, and Adjuvant Chemotherapy for High-Risk Extremity Soft Tissue Sarcoma. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[19]  R. Langer,et al.  PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapy , 2018, Oncoimmunology.

[20]  C. Antonescu,et al.  Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. , 2018, The Lancet. Oncology.

[21]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[22]  Steven J. M. Jones,et al.  Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas , 2017, Cell.

[23]  Jun Li,et al.  Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. , 2017, Cancer research.

[24]  F. Hodi,et al.  Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study , 2017, Cancer.

[25]  B. Bryan,et al.  PD-1 and PD-L1 expression in bone and soft tissue sarcomas. , 2017, Pathology.

[26]  Mei Zhang,et al.  Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis , 2017, Oncotarget.

[27]  Mei Zhang,et al.  Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis , 2017, Oncotarget.

[28]  U. Dirksen,et al.  Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets , 2017, bioRxiv.

[29]  E. Tartour,et al.  Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer , 2017, ESMO Open.

[30]  J. Blay,et al.  PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas , 2017, Oncoimmunology.

[31]  Y. Fujisawa,et al.  Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma , 2017, Oncoimmunology.

[32]  C. Denny,et al.  Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma , 2016, Cancer Immunology Research.

[33]  Jinming Yu,et al.  PD-L1 expression in human cancers and its association with clinical outcomes , 2016, OncoTargets and therapy.

[34]  Young Han Lee,et al.  Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma , 2016, BMC Cancer.

[35]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[36]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[37]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[38]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[39]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[40]  A. Daigeler,et al.  Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma , 2014, British Journal of Cancer.

[41]  R. Maki,et al.  A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma , 2013, Sarcoma.

[42]  J. Neal,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Sudo,et al.  Retrospective analysis of metastatic sarcoma patients. , 2011, Oncology letters.

[44]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[45]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .

[46]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.